The primary objective is to examine relationships between neurocognitive performance and MRI parameters of brain vasculature, metabolism, and white matter diffusion in children who have been treated for posterior fossa tumor. Secondary objectives…
ID
Source
Brief title
Condition
- Nervous system neoplasms malignant and unspecified NEC
Synonym
Research involving
Sponsors and support
Intervention
- Medical device
N.a.
Outcome measures
Primary outcome
<p>Age-standardized performance on a sustained attention task (K-CPT-2/CPT-3 measure) is the endpoint of the main analysis. The 7T MRI metrics measuring vasculature, metabolism, and white matter diffusion in the brain will be used to predict performance on this task.</p>
Secondary outcome
<p>Age-standardized performance on other neuropsychological measures (estimated IQ, working memory, processing speed, executive functioning, memory, visual-motor, questionnaires), clinical data (demographic, treatment, RT dose, complications), and premorbid history (birth, health, school, SES).</p>
Background summary
Treatment advances have increased survival rates for children with brain tumors. However, many survivors experience neurocognitive problems after treatment that significantly impact their quality of life and unfortunately there are few evidence-based interventions to improve cognitive deficits after they occur. These impairments are most prominent for children who were treated at a younger age or with cranial radiation therapy (RT), and thus, methods to prevent RT-related damage are an ongoing field of research.
There is increasing evidence that the early neurobiological changes that occur after brain tumor treatment are predictive of cognitive functioning in the long term. In this manner, assessment of changes in the brain may provide a marker of vulnerability for future cognitive dysfunction, although knowledge of early and sensitive biomarkers of cognitive decline is limited in children with brain tumors. Therefore, these results indicate that there is a critical need to identify early (bio)markers of neurocognitive decline, so that potential preventative strategies can be implemented prior to the onset of impairments.
This study addresses this knowledge gap by using newly developed, high field 7Tesla (T) Magnetic Resonance Imaging (MRI) techniques measuring vascular health, metabolism, and diffusion in the brain. Previous research has shown that 7T MRI can visualize brain structure and function in an unprecedented manner, including vascular lesions with resolutions of <1mm and brain pulsatility and metabolism in patients across the age range. Also, small vessel degeneration and low glutamate levels assessed with 7T MRI have previously been associated with worse cognitive performance in adult and pediatric populations. Furthermore, 7T MRI methods have been developed to assess microinfarcts in neurodegenerative diseases, which were then subsequently applied to 3T MRI scanners used in the clinic. These results suggest that 7T MRI techniques can detect brain structural or functional changes in a highly sensitive manner, which can then be applied to clinical settings. These techniques could be developed as an early predictive tool for cognitive deficits, although this has not yet been established for children with brain tumors. Results from the current study will inform future longitudinal research examining whether changes in brain vasculature, metabolism, and diffusion precede or accelerate cognitive decline over time. Ultimately, knowledge from this research can be used to direct treatment and prevent cognitive decline in pediatric brain tumor.
Study objective
The primary objective is to examine relationships between neurocognitive performance and MRI parameters of brain vasculature, metabolism, and white matter diffusion in children who have been treated for posterior fossa tumor. Secondary objectives are to examine relationships between RT dose distribution and neurocognitive outcomes and to evaluate whether the combination of multiple imaging modalities can distinguish between survivors who had relatively better versus poorer neurocognitive functioning.
Study design
Single center observational pilot study
Intervention
7T MRI, questionnaires, neuropsychological tests
Study burden and risks
Participants will come to the research facility at University Medical Center Utrecht (UMCU) to complete MR imaging at 7T (1 hr) and to the Princess Máxima Center to complete neuropsychological testing (2 hr). These appointments will be completed on the same day when possible. MRI is a non-invasive imaging modality, involving high magnetic fields, which in general is not associated with adverse events other than possible claustrophobia due to lying in the small MR bore. Additionally, some patients may experience some dizziness or
nausea. All participants will already have an MRI during normal clinical routine; therefore, we can exclude patients with severe claustrophobia.
Patients and parents/caregivers will also be asked to complete neuropsychological tests and questionnaires. Some patients will complete these tests as part of standard care, which therefore minimizes time burden. Furthermore, appointments will be combined with regularly scheduled appointments as much as possible, and there will be opportunities for breaks if needed. Most questionnaires can be completed at home through the secure online KLIK portal. There are no anticipated risks for participation.
One potential benefit is that parents will receive a summary of results from the assessments (and will be referred for services when needed). Otherwise, there are no direct benefits for participation and results will be used to optimize care for future patients.
M.H. Partanen
Heidelberglaan 25
Utrecht 3584 CS
Netherlands
+31 88 972 72 72
m.h.partanen@prinsesmaximacentrum.nl
M.H. Partanen
Heidelberglaan 25
Utrecht 3584 CS
Netherlands
+31 88 972 72 72
m.h.partanen@prinsesmaximacentrum.nl
Trial sites in the Netherlands
Listed location countries
Age
Inclusion criteria
- Age between 6 and 23 years old
- Have been treated for a posterior fossa brain tumor with surgery/chemotherapy only, focal proton radiotherapy, or cranial-spinal proton radiotherapy
- At least 6 months and up to 5 years after diagnosis, and completed treatment
- Able to complete MRI without anaesthesia
Exclusion criteria
- No signed informed consent (either by patient and/or parents/legal guardian)
- Insufficient knowledge of the Dutch language to perform the neuropsychological assessment or complete questionnaires
- Significant visual, motor, or developmental problems and thus alternative neuropsychological assessments would be needed (e.g., blindness, deafness, profound developmental delay)
- MRI-specific exclusion criteria, such as metal implants. Screening for MRI specific exclusion criteria will be done using the typical 7-Tesla MRI safety screening.
Design
Recruitment
Medical products/devices used
IPD sharing statement
Plan description
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
Register | ID |
---|---|
CCMO | NL79739.041.21 |
Research portal | NL-006204 |